Esperance is developing novel, targeted oncology product candidates that selectively kill cancer cells without harming normal cells. The cationic lytic peptide (CLYPTM) technolgy platform is delivering multiple membrane distupting peptides (MDPs) and antibody drug conjugates (ADCs).
|
Product Candidate |
Target |
Potential Indications |
Status |
|
EP-100 Peptide conjugate |
LHRH-Receptor |
Solid tumors (ovarian, breast, endometrial, prostate, pancreatic) and blood cancers |
Phase 2 |
|
EP-200 Peptide conjugate |
LH/hCG-Receptor |
Solid tumors (breast, prostate, endometrial, ovarian) |
Proof of concept demonstrated in vitro and in vivo |
|
EP-300 Peptide conjugates |
FSH-Receptor (anti-angiogenesis) |
Solid tumors and blood cancers |
Proof of concept demonstrated in vitro and in vivo |
|
Antibody drug conjugates (ADCs) |
HER2 and CD20 |
Solid tumors (breast, gastric, bladder) and blood cancers |
Production in bacteria, yeast and mammalian cells; in vitro activity demonstrated |